EMBC (Embecta) Other Stockholders Equity: $0 Mil (As of Mar. 2026)


EMBC Embecta Corp EMBC
53 GF Score
Price $3.35
GF Value $12.68
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Embecta Other Stockholders Equity?

Embecta EMBC -0.45% 53 Other Stockholders Equity is $0 Mil as of Mar. 2026. GuruFocus rates EMBC with a GF Score™ of 53/100 and a GF Value™ of $12.68 (Possible Value Trap). The stock has 6 warning signs investors should review.

Embecta's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0 Mil.

Embecta's annual Other Stockholders Equity increased from Sep. 2023 ($0 Mil) to Sep. 2024 ($0 Mil) but then declined from Sep. 2024 ($0 Mil) to Sep. 2025 ($0 Mil).

Embecta Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Embecta's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embecta Other Stockholders Equity Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Stockholders Equity
Get a 7-Day Free Trial 864.80 0.00 0.00 0.00 0.00

Embecta Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
EMBC
53GF Score
Embecta Corp EMBC
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Embecta Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0 Mil mean?
Embecta (EMBC) has a Other Stockholders Equity of $0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Embecta and its competitors.
Is Embecta's Other Stockholders Equity too high?
Embecta's current Other Stockholders Equity is $0 Mil. Overall, Embecta has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Embecta's Other Stockholders Equity compare to KRMD and SMTI?
Embecta's Other Stockholders Equity of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Embecta and its competitors. Embecta's current Other Stockholders Equity is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Based on GuruFocus' analysis, Embecta (EMBC) is currently considered Possible Value Trap. The stock's GF Value™ is $12.68, compared to a current price of $3.35 — trading 73.6% below its estimated fair value. The current Other Stockholders Equity is $0 Mil. Embecta's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Embecta (EMBC), the current Other Stockholders Equity is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embecta (EMBC) Overvalued in 2026?

Based on GuruFocus' analysis, Embecta stock appears to be undervalued. The current stock price of $3.35 is trading 73.6% below its estimated GF Value™ of $12.68. GuruFocus considers Embecta to be Possible Value Trap.

Key valuation signals for EMBC:

  • Other Stockholders Equity: $0 Mil
  • GF Value™: $12.68 vs. price of $3.35 (73.6% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embecta Business Description

Other Exchanges JX7:Germany
Address 300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score

Get the complete analysis for EMBC

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price
$12.68
GF Value